2023 World Conference on Lung Cancer (Posters)-P2.18. Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma

P2.18. Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma - PDF(Abstract)

Back to course

Pdf Summary

Researchers have successfully generated tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy from mesothelioma, according to a study presented at WCLC 2023. Mesothelioma patients have a poor prognosis, with a median survival of only 18 months. The standard of care is immune checkpoint inhibitor therapy followed by systemic chemotherapy, but patients often progress within seven months. There is a need for novel effective therapies. Adoptive cell therapy with autologous TIL uses a portion of the patient's tumor to develop personalized immunotherapy. TIL cell therapy has shown efficacy in other solid tumors, and this study investigates its potential in mesothelioma.<br /><br />The researchers collected tissue samples from six patients with mesothelioma during routine pleurectomy decortication. The samples were processed using a small-scale 22-day manufacturing process. The TIL products were evaluated for dose, purity, identity, and activity. The results showed that the final TIL products met acceptance criteria in five out of six tumor samples, with a median total viable cell count of 53.4 million cells/mL, a purity of 90.1%, and an identity phenotype of 98.8%. The TIL cells also showed functional responses to polyclonal bead stimulation, with median interferon-gamma levels of 4454 pg/mL. The TIL products exhibited mixed populations of CD4 and CD8 T-cells.<br /><br />These findings suggest that viable TIL can be successfully expanded from mesothelioma tumor tissue using this 22-day manufacturing process. This supports the potential clinical investigation of TIL cell therapy as a treatment option for patients with mesothelioma. The study highlights the importance of developing novel therapies that harness the patient's immune system to improve outcomes in mesothelioma. Further research and clinical trials are needed to determine the efficacy and safety of TIL cell therapy in this patient population.

Asset Subtitle

Dean Fennell

Meta Tag

Speaker Dean Fennell

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

tumor-infiltrating lymphocytes

adoptive cell therapy

mesothelioma

WCLC 2023

immune checkpoint inhibitor therapy

personalized immunotherapy

solid tumors

manufacturing process

clinical investigation

clinical trials